Marker Therapeutics, Inc., a clinical-stage immuno-oncology company focusing on next-generation T cell immunotherapies, announced that CEO Dr. Juan Vera will participate in a live webcast on May 28, ...

Marker Therapeutics (MRKR) reports clinical updates in APOLLO trial for the treatment of lymphoma patients who have relapsed after anti-CD19 CAR T cell therapy Patient with Non-Hodgkin’s Lymphoma who ...

Marker Therapeutics, Inc. provided an update on its Phase 1 APOLLO study of MT-601, a novel T cell therapy targeting relapsed lymphoma patients. The study reported an objective response rate of 78% ...

HOUSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (MRKR) (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies ...

A woman in her thirties who was dependent on blood transfusions and unresponsive to every standard treatment for her three ...

B-cell acute lymphoblastic leukemia (B-ALL) is the most common cancer in children, accounting for around 85% of pediatric leukemia cases. According to REDECAN, more than 400 new cases are estimated to ...

In the treatment of aggressive lymphomas and blood cancer (leukemia), so-called chimeric antigen receptor T cells (CAR T cells) are increasingly being used. For this therapy, immune cells are taken ...

In the treatment of aggressive lymphomas and blood cancer (leukaemia), so-called chimeric antigen receptor T cells (CAR T cells) are increasingly being used. For this therapy, immune cells are taken ...

HOUSTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for ...